论文部分内容阅读
本文研究降脂药 gemfibrozil 对高胆固醇血症患者在静息时和亚板量运动中血小板反应性的影响。平均45(34～57)岁的10例男性高胆固醇血症(Ⅱ_b 型和Ⅱ_a 型各5例)患者作为对象,其血清胆固醇含量均>270mg/dl,且未经治疗。凡有继发性高胆固醇血症、心血管疾病或者影响预后的其它疾病者已除外。试验按照随机、双盲和交叉的方式进行。每例服用 gemfibrozil(600mg,tid)和安慰剂各8周,其间停药8周。每疗程末作分级蹬车试验(12分钟内使心率达到预期最大心率的
This article studies the effect of gemfibrozil, a lipid-lowering drug, on platelet reactivity in patients with hypercholesterolemia at rest and in subplate volume. A total of 45 (34-57) years of age, 10 cases of male hypercholesterolemia (Ⅱ_b type and Ⅱ a type of 5 patients) as a target, the serum cholesterol levels were> 270mg / dl, and untreated. Where there are secondary hypercholesterolemia, cardiovascular disease or affect the prognosis of other diseases have been excluded. The trials were conducted in a randomized, double-blind and crossover manner. Each of gemfibrozil (600 mg, tid) and placebo was administered for 8 weeks, with discontinuation for 8 weeks. At the end of each treatment for grading treadmill test (12 minutes to reach the maximum heart rate heart rate